论文信息 - Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. - 字舞流文

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

M. Rebelatto | M. Borad | G. Abou-Alfa | R. Kelley | B. Sangro | Tae-You Kim | Yoon-Koo Kang | J. Bendell | M. Morse | W. Yong | S. Morris | Feng Xiao | M. Makowsky